Format

Send to

Choose Destination
Am J Infect Control. 2018 Jan;46(1):100-102. doi: 10.1016/j.ajic.2017.06.010. Epub 2017 Jul 27.

Underutilization of norovirus testing in hematopoietic cell transplant recipients at a large cancer center.

Author information

1
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Infection Prevention, Seattle Cancer Care Alliance, Seattle, WA.
2
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
3
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle, WA.
4
Department of Laboratory Medicine, University of Washington, Seattle, WA.
5
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Infection Prevention, Seattle Cancer Care Alliance, Seattle, WA; Department of Medicine, University of Washington, Seattle, WA. Electronic address: spergam@fhcrc.org.

Abstract

The development of a new laboratory-developed norovirus assay provided an opportunity to assess testing patterns, incidence, and outcomes of norovirus among hematopoietic cell transplant (HCT) recipients. Clostridium difficile and norovirus tests from 1,393 HCT recipients were compared in these analyses. In this population of high-risk patients, norovirus appeared to occur seasonally, but testing was infrequent despite a correlation with more severe disease when compared with patients with C difficile infection.

KEYWORDS:

Clostridium difficile; Diagnostics; Diarrhea; Norovirus; Transplant

PMID:
28757083
DOI:
10.1016/j.ajic.2017.06.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center